Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02307149 · ClinicalTrials.gov registry record · Phase 1
Intratumoral CAVATAK (CVA21) and Ipilimumab in Patients With Advanced Melanoma (VLA-013 MITCI)
A Phase 1 study, sponsored by Viralytics.
- Completed
- Registry status
- Phase 1
- Development phase
- 50
- Enrollment target
NCT02307149: Completed Phase 1 study, sponsored by Viralytics.
NCT02307149 is a Phase 1 study that has completed, run by Viralytics. The registered enrollment target is 50 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (17% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02307149, a Phase 1 study, has completed, sponsored by Viralytics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 50 participants
- Enrollment target
Study Summary
Open label, single arm study of intratumoral CVA21 and ipilimumab in advanced melanoma patients.
Primary Outcome
Best response of complete response (CR) or partial response (PR)
Interventions
- DRUG Ipilimumab
- BIOLOGICAL CAVATAK
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2015-05-05 |
| Est. Completion | 2019-11-05 |
| Phase | Phase 1 |
What the finished NCT02307149 record still lists
NCT02307149 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (17% lower).
The record links to 0 conditions, and to 2 interventions - of which Ipilimumab is the first listed.
NCT02307149 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02307149 about?
NCT02307149 is a clinical study titled "Intratumoral CAVATAK (CVA21) and Ipilimumab in Patients With Advanced Melanoma (VLA-013 MITCI)". Open label, single arm study of intratumoral CVA21 and ipilimumab in advanced melanoma patients.
What is the current status of trial NCT02307149?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2015-05-05. Estimated completion is 2019-11-05.
What interventions are being tested in trial NCT02307149?
The interventions under investigation include: Ipilimumab (DRUG), CAVATAK (BIOLOGICAL).
Who is sponsoring clinical trial NCT02307149?
This trial is sponsored by Viralytics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02307149's enrollment target sits among peer trials
50 973rd of 2000 higher than 984 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI